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Inflammatory Mediators and Cell Adhesion Molecules as
Indicators of Severity of Atherosclerosis
The Rotterdam Study
Irene M. van der Meer, Moniek P.M. de Maat, Michiel L. Bots, Monique M.B. Breteler, John Meijer,
Amanda J. Kiliaan, Albert Hofman, Jacqueline C.M. Witteman
Abstract—Inflammatory mediators and soluble cell adhesion molecules predict cardiovascular events. It is not clear
whether they reflect the severity of underlying atherosclerotic disease. Within the Rotterdam Study, we investigated the
associations of C-reactive protein (CRP), interleukin-6 (IL-6), soluble intercellular adhesion molecule-1, and soluble
vascular cell adhesion molecule-1 with noninvasive measures of atherosclerosis. Levels of CRP were assessed in a
random sample of 1317 participants, and levels of IL-6 and soluble cell adhesion molecules were assessed in a
subsample of 714 participants. In multivariate analyses, logarithmically transformed CRP (regression coefficient
[]0.023, 95% CI 0.033 to 0.012) and IL-6 (0.025, 95% CI 0.049 to 0.001) were inversely associated
with the ankle-arm index. Only CRP was associated with carotid intima-media thickness (0.018, 95% CI 0.010 to
0.027). Compared with the lowest tertile, the odds ratio for moderate to severe carotid plaques associated with levels
of CRP in the highest tertile was 2.0 (95% CI 1.3 to 3.0). Soluble intercellular adhesion molecule-1 levels were strongly
associated with carotid plaques (odds ratio 2.5, 95% CI 1.5 to 4.4 [highest versus lowest tertile]). Soluble vascular cell
adhesion molecule-1 was not significantly associated with any of the measures of atherosclerosis. This study indicates
that CRP is associated with the severity of atherosclerosis measured at various sites. Associations of the other markers
with atherosclerosis were less consistent. (Arterioscler Thromb Vasc Biol. 2002;22:838-842.)
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Over the past years, it has been recognized that inflammationmay contribute to all stages of the atherosclerotic process.1
C-reactive protein (CRP), an acute-phase protein that is mainly
regulated by the cytokine interleukin-6 (IL-6), is a sensitive
marker of inflammation. In several prospective studies, high
levels of CRP and IL-6 predicted coronary events in patients
with stable or unstable angina and in healthy subjects.2–4 Other
molecules that have been suggested to contribute to atheroscle-
rosis and its clinical outcomes are the endothelial cell adhesion
molecules (CAMs), which facilitate the emigration of leukocytes
into the vessel wall, an important feature of atherosclerotic
plaque formation.5 Indeed, high levels of soluble intercellular
adhesion molecule-1 (sICAM-1) have been shown to predict
myocardial infarction in the Physicians’ Health Study and the
Atherosclerosis Risk in Communities study.6,7
The presence of CRP, IL-6, ICAM-1, and vascular cell adhesion
molecule-1 (VCAM-1) has been demonstrated in atherosclerotic
lesions.8–10 Moreover, levels of CRP and IL-6 have been positively
related to peripheral and coronary artery disease in selected patient
populations,11,12 although Folsom et al13 recently concluded that
CRP is not a strong marker of prevalent atherosclerosis. sICAM-1
has shown a positive relationship with peripheral arterial disease,14
established by angiography or ultrasound, whereas soluble
VCAM-1 (sVCAM-1) has been related to the extent of atheroscle-
rosis, established angiographically in multiple vascular beds in
patients with peripheral arterial disease.15 In various populations,
soluble CAMs (sCAMs) have been positively related to common
carotid intima-media thickness (IMT).6,16,17
Most of the studies involving inflammatory mediators or
adhesion molecules and atherosclerosis have been based on
patient series. In the Rotterdam Study, a population-based
cohort study of men and women aged 55 years, we
investigated whether plasma levels of CRP, IL-6, sICAM-1,
and sVCAM-1 are associated with the severity of atheroscle-
rosis, measured at various sites of the arterial tree.
Methods
Population
The Rotterdam Study is a prospective population-based cohort study
composed of 7983 men and women aged 55 years. Its overall aim
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is to investigate the incidence of and risk factors for chronic
disabling diseases. From 1990 until 1993, all inhabitants of a suburb
of the city of Rotterdam aged 55 years were invited to participate
in an extensive home interview and 2 visits to the research center.
The overall response rate was 78%. The Medical Ethics Committee
of the Erasmus University Rotterdam approved the Rotterdam Study,
and written informed consent was obtained from all participants. For
the present study, levels of CRP were assessed in a randomly
selected age- and sex-stratified sample of 1317 participants. Levels
of IL-6, sICAM-1, and sVCAM-1 were assessed in a random
subsample of 714 participants. A more detailed description of the
Rotterdam Study and of the collection of data has been provided
elsewhere.18,19
Measures of Atherosclerosis
By use of a random zero sphygmomanometer, sitting blood pressure
was measured at the right upper arm. The average of 2 measurements
obtained on 1 occasion was used. Systolic blood pressure at the
ankles (posterior tibial artery) was measured with subjects in the
supine position with a random zero sphygmomanometer and an
8-MHz continuous-wave Doppler probe (Huntleigh 500D, Huntleigh
Technology). The ratio of the systolic blood pressure at the ankle to
the systolic blood pressure at the arm was computed to obtain the
ankle-arm index (AAI). For the analyses, we used the lowest value
of the 2 legs. Because arterial rigidity prevents arterial compression
and will therefore lead to spurious high values of the AAI, an AAI
1.50 was considered invalid.19
Ultrasonography of both carotid arteries was performed with a
7.5-MHz linear-array transducer and a duplex scanner (ATL Ultra-
Mark IV). Common carotid IMT was determined as the average of
near-wall and far-wall measurements, and the average of left and
right common carotid IMT was computed.20
Carotid plaques were defined as a focal widening relative to
adjacent segments, with the protrusion into the lumen composed of
only calcified deposits or of a combination of calcification and
noncalcified material.20 A plaque score ranging from 0 to 1 was
derived by dividing the number of sites (left and right side of the
common carotid artery, carotid bifurcation, and internal carotid
artery) with a detectable plaque by the total number of sites (with a
maximum of 6) for which an ultrasonographic image was available.
To indicate the presence of moderate or severe carotid plaques, we
used cutoff points of 0.5 and 0.75, respectively.
Aortic atherosclerosis was diagnosed by radiographic detection of
calcified deposits in the abdominal aorta on a lateral abdominal film.
The extent of abdominal aortic atherosclerosis was scored according
to the length of the involved area (with scores 0 to 5 corresponding
to 0, 1 cm, 1 to 2.5 cm, 2.5 to 4.9, 5.0 to 9.9, and 10.0 cm).21 A
calcification score of 3 was considered moderate, and scores 4 and 5
were considered severe.
Inflammatory Mediators and CAMs
For logistic reasons, CRP was measured by 2 sensitive immunolog-
ical methods, an in-house enzyme immunoassay (n603 subjects,
DAKO) and a nephelometric method (n714, Dade-Behring). These
2 methods demonstrate a high level of agreement.22 CRP was
measured by both methods in 134 subjects. For each of these subjects
with values of CRP10 mg/L, we plotted the difference between the
logarithmically transformed results of the 2 methods against the
mean of the 2 methods.23 The plot showed no systematic relationship
between the difference and the mean of the paired measurements,
and the 2 methods showed good agreement. The mean difference in
CRP was 0.036 mg/L. To ascertain that differences in the distribution
of CRP for the 2 methods had not influenced the results, we
standardized the 2 distributions of CRP by computing z scores (value
minus mean, divided by the SD of the mean). We repeated all
analyses by using the standardized data and found results similar to
the ones reported in the present study.
IL-6, sICAM-1, and sVCAM-1 were measured by using commer-
cially available ELISA (IL-6, Quantikine HS; sICAM-1 and
sVCAM-1, Parameter; all assays were from R&D Systems Europe).
Outliers (values 3 SDs of the population distribution) of logarith-
mically transformed CRP (n4) and IL-6 (n9) and of sICAM-1
(n13) and sVCAM-1 (n13) were excluded because they may
indicate the presence of an active inflammatory disease. In the study
population, 5.2% had levels of CRP 10 mg/L.
Statistical Analysis
We used logarithmically transformed values of CRP and IL-6 to
normalize the distribution of these variables. Cutoff points for tertiles
were 1.11 and 2.77 mg/L for CRP, 1.44 and 2.43 pg/mL for IL-6,
190.1 and 231.4 ng/mL for sICAM-1, and 451.8 and 574.8 ng/mL for
sVCAM-1. We estimated partial correlations between inflammatory
mediators and sCAMs. Mean values of the AAI and IMT were
computed for increasing tertiles of CRP, IL-6, sICAM-1, and
sVCAM-1 by means of ANCOVA. We tested linearity by using
linear regression analysis with the AAI and IMT as dependent
variables. Logistic regression analysis was used to compute odds
ratios (ORs, for the higher tertiles of inflammatory mediators and
sCAMs compared with the lowest tertile) of having moderate to
severe carotid plaques and abdominal aorta calcifications. Analyses
involving CRP were adjusted for the method used to measure CRP
levels. All analyses were adjusted for age, sex, smoking status
(current, past, or never smokers), and pack-years of smoking and
additionally for body mass index (BMI) and diabetes mellitus.
Analyses were performed by using SPSS 9.0 for Windows.
Results
Baseline characteristics of the study population are shown in
Table 1. Baseline characteristics of the subsample of 714
participants were similar to those of the total sample.
CRP and IL-6, as well as sICAM-1 and sVCAM-1, were
moderately correlated (r0.56 and r0.27, respectively;
P0.001; Table 2). CRP and IL-6 were both correlated with
sICAM-1 (r0.20 and r0.21, respectively; P0.001).
Increasing tertiles of CRP and IL-6 were inversely associ-
ated with the AAI. In linear regression analysis, the regres-
sion coefficients ( values) were 0.026 (95% CI 0.036 to
TABLE 1. Baseline Characteristics of the Study Population
Variable
All Subjects
(n1317)
Subsample
(n714)
Age, y 71.28.9 71.69.0
Sex, % men 46.3 47.2
Body mass index, kg/m2 26.33.6 26.43.6
Systolic blood pressure, mm Hg 138.821.5 138.421.0
Total cholesterol, mmol/L 6.61.2 6.61.2
HDL-cholesterol, mmol/L 1.30.4 1.30.4
Current smokers, % 19.3 19.9
Diabetes mellitus, % 9.5 8.3
History of myocardial infarction, % 15.1 14.9
Carotid plaques, %* 27.2 25.0
Aorta calcifications, %† 32.3 30.9
C-reactive protein, mg/L‡ 1.82 (0.85 to 3.68) 1.73 (0.81 to 3.68)
Interleukin-6, pg/mL‡    1.91 (1.25 to 3.13)
sICAM-1, ng/mL    223.769.9
sVCAM-1, ng/mL    542.6184.5
Data are meansSD for continuous variables and percentages for dichot-
omous variables.
*Defined as a plaque score (range, 0 to 1) larger than 0.5.
†Defined as a calcification score (range, 0 to 5) larger than 3.
‡For data with a skewed distribution, the median and interquartile range are
shown.
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0.016) and 0.034 (95% CI 0.057 to 0.011) for
logarithmically transformed values of CRP and IL-6, respec-
tively. After adjustment for BMI and diabetes mellitus, the
associations of CRP (0.023, 95% CI0.033 to0.012)
and IL-6 (0.025, 95% CI 0.049 to 0.001) with the
AAI remained. The data presented in Figure 1 are based on
the fully adjusted model. sCAMs were not linearly associated
with the AAI.
CRP was significantly linearly associated with IMT before
(0.021, 95% CI 0.013 to 0.029) and after (0.018, 95%
CI 0.010 to 0.027; Figure 2) additional adjustment for BMI
and diabetes mellitus. IL-6 and sCAMs were not associated
with IMT.
Compared with the lowest tertile, ORs for carotid plaques
associated with levels of CRP and sICAM-1 in the highest
tertile were 2.0 (95% CI 1.3 to 2.9) and 2.6 (95% CI 1.5 to
4.5), respectively (Table 3). For IL-6 and sVCAM-1, there
was a comparable, but not statistically significant, trend.
Associations of CRP and sICAM-1 with carotid plaques were
very robust; the association between IL-6 and carotid plaques
was somewhat weaker after adjustment for BMI and diabetes
mellitus (OR 1.5, 95% CI 0.8 to 2.7).
Only sICAM-1 was of borderline statistical significance in
its association with abdominal aorta calcifications (OR 1.7,
95% CI 1.0 to 3.1; Table 3). For IL-6, there was a similar
trend. After adjustment for BMI and diabetes mellitus, the
association of sICAM-1 with aortic calcifications (OR 1.6,
95% CI 0.9 to 2.9) was slightly weaker.
To take possible changes in lifestyle and medication use in
participants with a clinically manifest myocardial infarction
in the past into account, we repeated all analyses with
additional adjustment for past myocardial infarction and for
aspirin and statin use at baseline. Associations of inflamma-
tory mediators and adhesion molecules with measures of
atherosclerosis were not meaningfully different (data not
shown).
Discussion
This population-based study in elderly subjects shows that
CRP is related to the severity of atherosclerosis at various
sites of the arterial tree. Although the results of the present
study suggest that IL-6 and sICAM-1 are also associated with
atherosclerosis, associations of these markers with measures
of atherosclerosis were less consistent.
In the present study, we examined multiple inflammatory
mediators in relation to multiple measures of atherosclerosis
in a population-based setting. There are several methodolog-
ical issues that need to be discussed before interpreting these
data. First, we used different methods and different parts of
the vascular tree to assess the severity of atherosclerosis. The
AAI represents the amount of atherosclerotic disease distal to
the aortic bifurcation, but it may also be influenced by
hemodynamic factors and vascular stiffness. Carotid IMT and
plaques reflect atherosclerosis in the carotid vessel wall,
although it cannot be excluded that nonatherosclerotic pro-
cesses, such as fibromuscular hypertrophy, cause modest
degrees of intima-media thickening.24 Radiographically as-
sessed calcifications of the abdominal aorta have been shown
to be highly specific, representing advanced intimal athero-
sclerosis.25 Second, we have presented our results with and
without additional adjustment for BMI and diabetes mellitus.
It has recently been reported that adipose tissue is an
important source of cytokine production26 and adjusting for
BMI will substantially lower the variation in levels of
inflammatory mediators. Furthermore, inflammation has been
suggested to be a triggering factor in the origin of diabetes
mellitus,27 which implies that diabetes mellitus may be an
intermediate factor rather than a confounder. Adjusting for
BMI and diabetes mellitus is indicated only if one wants to
examine whether the association of inflammation with ath-
erosclerosis is independent of these variables. Third, levels of
CRP, IL-6, sICAM-1, and sVCAM-1 were measured only
once. Therefore, intraindividual variation, as has been re-
ported for CRP and IL-6,28,29 cannot be taken into account.
Figure 1. Mean AAI by tertiles of CRP, IL-6, sICAM-1, and
sVCAM-1. Bars represent means, and lines represent SEM.
Means are adjusted for age, sex, smoking status, pack-years of
smoking, BMI, and diabetes mellitus. *P for trend0.001; †P for
trend0.04.
Figure 2. Mean IMT (mm) of the common carotid artery by ter-
tiles of CRP, IL-6, sICAM-1, and sVCAM-1. Bars represent
means, and lines represent SEM. Means are adjusted for age,
sex, smoking status, pack-years of smoking, BMI, and diabetes
mellitus. *P for trend0.001.
TABLE 2. Partial Correlations Between Inflammatory
Mediators and Soluble Cell Adhesion Molecules
IL-6* sICAM-1 sVCAM-1
CRP* 0.56† 0.20† 0.04
IL-6*    0.21† 0.09‡
sICAM-1       0.27†
Correlations are adjusted for age, sex, smoking status, and pack-years of
smoking.
*For CRP and IL-6 log-transformed values are used.
†P0.001. ‡P0.02.
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However, such variation will likely result in an underestima-
tion of the true relationship.
Many studies have found a relationship between CRP and
the risk of myocardial infarction in the general population.3 In
addition, levels of CRP and IL-6 were positively related to
peripheral and coronary artery disease in selected patient
populations.11,12 The present study is the first to show a
positive association between inflammation, represented by
levels of CRP and IL-6, and severity of atherosclerosis in a
population-based study in the elderly.
IL-6 is the principal determinant of the hepatic synthesis of
CRP. In the present study, CRP is linearly associated with
carotid IMT, whereas IL-6 is not. A possible explanation for the
discrepancy between CRP and IL-6 is the substantial intraindi-
vidual variation in levels of IL-6.29 Although associations with
different measures of atherosclerosis are more consistent for
CRP than for IL-6, it is likely that levels of CRP reflect general
inflammatory activity. However, specific actions of CRP itself
may also be involved in atherogenesis.30,31
CRP was not associated with the presence of abdominal
aortic calcifications. This suggests that once atherosclerotic
plaques have reached the stage in which they are calcified,
inflammation is no longer one of the main features of these
plaques. Similarly, several cross-sectional studies have re-
ported a lack of association of CRP with coronary calcifica-
tions as measured by electron-beam tomography.32,33
Because the acute-phase response may be induced by
damage to the vascular endothelium caused by atherosclerotic
processes, plasma levels of inflammatory mediators may
simply represent the extent of atherosclerotic disease. Alter-
natively, however, increased local or systemic inflammation
due to chronic infection, chronic inflammatory diseases,
smoking, obesity, or impaired glucose tolerance26,34,35 may
precede (the progression of) atherosclerosis.36 Because of the
cross-sectional design of the present study, it is not possible
to draw conclusions about the direction of the associations
between inflammatory mediators and atherosclerosis.
CAMs may be important in atherosclerosis, inasmuch as they
facilitate the emigration of leukocytes into the vessel wall.5
Pathological studies have shown that CAMs are expressed on
atherosclerotic plaques,10 and in mice, a deficiency of CAMs
appeared to protect against atherosclerosis.37 sCAMs are likely
to be the result of shedding from atherosclerotic plaques,38 and
they are thought to represent the severity of atherosclerosis.
However, reports on adhesion molecules and atherosclerosis are
not consistent. Several studies have reported significant associ-
ations of only sICAM-1,6,14 only sVCAM-1,15,16 or both
sCAMs17 with measures of atherosclerosis.
It is not clear what accounts for the diversity of the
associations found between sCAMs and atherosclerosis. The
populations that have been studied varied substantially in the
degree of atherosclerosis, and atherosclerosis has been mea-
sured at different sites of the arterial tree. In the present study,
sICAM-1, but not sVCAM-1, was significantly correlated
with CRP and IL-6, and the ORs for carotid plaques and
aortic calcifications associated with high levels of sICAM-1
were increased. sVCAM-1 was not related to atherosclerosis.
The present study adds to the understanding that sICAM-1
and sVCAM-1 are likely to have different roles in atherogen-
esis or the progression of atherosclerosis. Moreover, whereas
CRP was strongly associated with the AAI and IMT,
sICAM-1 was not. More research, at the molecular level and
at the population level, is necessary to elucidate the role of
CAMs in atherosclerosis.
In the present study, associations with measures of atheroscle-
rosis were more consistent for CRP than for IL-6. Because
relatively cheap, automated, high-sensitivity methods for CRP
measurement have become commercially available,39 measure-
ment of CRP will be the most useful once inflammatory markers
are routinely assessed in clinical settings.
We conclude that CRP is associated with the severity of
atherosclerosis at various sites of the arterial tree. Associations
of IL-6 and sCAMs with atherosclerosis are less consistent.
TABLE 3. Odds Ratios for Carotid Plaques and Abdominal Aorta Calcifications Associated
With Increasing Tertiles of Inflammatory Mediators and Cell Adhesion Molecules
Tertiles of Plasma Level Tertiles of Plasma Level*
1 2 3 1 2 3
Carotid plaques†
CRP 1.0 1.5 (1.0 to 2.3) 2.0 (1.3 to 2.9) 1.0 1.6 (1.0 to 2.4) 2.0 (1.3 to 3.0)
IL-6 1.0 1.4 (0.8 to 2.5) 1.7 (0.9 to 3.0) 1.0 1.4 (0.8 to 2.5) 1.5 (0.8 to 2.7)
sICAM-1 1.0 1.5 (0.9 to 2.5) 2.6 (1.5 to 4.5) 1.0 1.4 (0.8 to 2.4) 2.5 (1.5 to 4.4)
sVCAM-1 1.0 1.4 (0.8 to 2.3) 1.5 (0.9 to 2.6) 1.0 1.4 (0.8 to 2.4) 1.6 (0.9 to 2.7)
Abdominal aorta calcifications‡
CRP 1.0 1.3 (0.8 to 1.9) 1.3 (0.9 to 2.0) 1.0 1.2 (0.8 to 1.9) 1.2 (0.8 to 1.9)
IL-6 1.0 1.4 (0.8 to 2.6) 1.7 (0.9 to 3.1) 1.0 1.4 (0.8 to 2.5) 1.5 (0.8 to 2.8)
sICAM-1 1.0 1.6 (0.9 to 2.8) 1.7 (1.0 to 3.1) 1.0 1.6 (0.9 to 2.9) 1.6 (0.9 to 2.9)
sVCAM-1 1.0 1.6 (0.9 to 2.9) 1.1 (0.6 to 1.9) 1.0 1.6 (0.9 to 2.9) 1.1 (0.6 to 1.9)
All analyses are adjusted for age, sex, smoking status, and pack-years of smoking.
*Additionally adjusted for body mass index and diabetes mellitus.
†Defined as a plaque score (range, 0 to 1) larger than 0.5.
‡Defined as a calcification score (range, 0 to 5) larger than 3.
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